Home > Boards > US Listed > Medical - Drugs > Athenex (ATNX)

DCTH acquisition/strategic partnership with ATNX imminent 

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Leotrader211 Member Profile
 
Followed By 3
Posts 504
Boards Moderated 0
Alias Born 09/18/17
160x600 placeholder
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 5/15/2019 6:16:48 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/9/2019 8:40:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 7:06:45 AM
Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/9/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/8/2019 5:06:58 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/8/2019 4:55:40 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/8/2019 4:02:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2019 8:06:56 AM
Athenex Announces $100 Million Private Placement GlobeNewswire Inc. - 5/6/2019 8:00:00 AM
Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire Inc. - 5/3/2019 9:12:18 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/25/2019 4:11:44 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 7:03:49 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:03 AM
Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire Inc. - 4/25/2019 7:00:00 AM
Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire Inc. - 4/23/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:26:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:23:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:15:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/17/2019 4:11:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:28:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:25:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:21:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/9/2019 4:11:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2019 4:30:06 PM
Leotrader211   Monday, 01/29/18 07:07:14 AM
Re: None
Post # of 14 
DCTH acquisition/strategic partnership with ATNX imminent 

Athenex allocating proceeds for acquisition. 
See the bold part under use of proceeds and delivery of common stock on Jan 29,2018. TIMING IS IMPECCABLE FOR COINCIDENCE 


USE OF PROCEEDS 

We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $61.2 million, or $70.5 million if the underwriters fully exercise their option to purchase additional shares, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. 

The principal purpose of this offering is to further increase our financial flexibility. We currently expect to use the net proceeds from this offering as follows: 

  

 • approximately $30.0 million for clinical development and regulatory activities for clinical products developed from our Orascovery platform; 

  

 • approximately $10.0 million for clinical development and regulatory activities for clinical products developed from our Src Kinase Inhibition platform; 

  

 • approximately $10.0 million for other clinical and pre-clinical research and development activities; and 

  

 • the remainder for working capital, capital expenditures and general corporate purposes. 

We may use a portion of the net proceeds of this offering for the acquisition or licensing, as the case may be, of additional technologies, other assets or businesses, or for other strategic investments or opportunities, although we have no definitive understandings, agreements or commitments to do so as of the date hereof. 

Delivery of the shares of our common stock is expected to be made on or about January 29, 2018



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist